- Home
- UHG vs PLX Comparison
UHG vs PLX Comparison
Compare UHG & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- PLX
- Stock Information
- Founded
- UHG 2004
- PLX 1993
- Country
- UHG United States
- PLX United States
- Employees
- UHG N/A
- PLX N/A
- Industry
- UHG Homebuilding
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UHG Consumer Discretionary
- PLX Health Care
- Exchange
- UHG Nasdaq
- PLX Nasdaq
- Market Cap
- UHG 248.7M
- PLX 204.9M
- IPO Year
- UHG N/A
- PLX 1998
- Fundamental
- Price
- UHG $2.00
- PLX $2.15
- Analyst Decision
- UHG
- PLX Strong Buy
- Analyst Count
- UHG 0
- PLX 1
- Target Price
- UHG N/A
- PLX $15.00
- AVG Volume (30 Days)
- UHG 111.3K
- PLX 1.1M
- Earning Date
- UHG 11-06-2025
- PLX 11-13-2025
- Dividend Yield
- UHG N/A
- PLX N/A
- EPS Growth
- UHG N/A
- PLX N/A
- EPS
- UHG 0.10
- PLX 0.08
- Revenue
- UHG $445,963,017.00
- PLX $61,948,000.00
- Revenue This Year
- UHG N/A
- PLX $14.53
- Revenue Next Year
- UHG N/A
- PLX $75.77
- P/E Ratio
- UHG $44.59
- PLX $24.02
- Revenue Growth
- UHG 7.51
- PLX 62.79
- 52 Week Low
- UHG $1.60
- PLX $1.01
- 52 Week High
- UHG $6.93
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- UHG 21.11
- PLX 48.79
- Support Level
- UHG $3.91
- PLX $1.60
- Resistance Level
- UHG $4.78
- PLX $2.55
- Average True Range (ATR)
- UHG 0.24
- PLX 0.16
- MACD
- UHG -0.12
- PLX -0.06
- Stochastic Oscillator
- UHG 2.38
- PLX 51.18
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.